Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Fintech PR

InnoVEX Returns in 2019 for New Thinking, New Engineering, and New Future

Published

on

Reading Time: 4 minutes

 

InnoVEX is the startup focused special exhibition of COMPUTEX. Started in 2016, the event has continued to see significant growth every year. InnoVEX saw a 20% growth between 2018 and 2019; with current exhibitors numbering 467 startup teams from 24 countries & regions and over 20,000 visitors expected to join InnoVEX. To ensure a better, more comfortable experience for the large number of expected visitors, exhibitors, and VIPS; InnoVEX will be held in a larger venue: TWTC Hall 1.

Being related to COMPUTEX puts InnoVEX in a special position as both visitors and exhibitors of COMPUTEX can freely enter InnoVEX showgrounds. This means InnoVEX exhibitors can get a targeted audience who are especially interested in ICT and innovation; including potential investors, customers, or buyers.

7 Main Topics of Forum, Over 40 Speakers

The 2019 InnoVEX Forum will take place from May 29 – 31 in the InnoVEX Center Stage. This year, the forum covers a wide range of topics: AI, Biotech, Blockchain, IoT Application, Smart Machinery, Sports Tech, and Startup Ecosystem. In the InnoVEX Forum, over 40 speakers from leading companies, accelerators and investors around the world will share their insights on the topics through keynote speeches and panel discussions.

Advertisement
Stake.com

This year, the speaker will include:

  • John Jorritsma, Mayor of Eindhoven who will share his insights on the opportunities and use cases of blockchain applications in smart cities
  • Zvika Popper, the VP of Strategy of HYPE Sports Innovation. Mr. Popper will speak about the sportstech ecosystem, the business models, and how the relation between fans and athletes all contribute to the sportstech ecosystem.
  • Ravi Belani, the Managing Director of Alchemist Accelerator. Joining a panel discussion as a representative of Silicon Valley Accelerators, Mr. Belani will share the methods to connect with global accelerators to the panel audience.
  • Dominik Schiener, the Co-Chairman of the Boards of Directors & Founder of IOTA Foundation. He will give a keynote and join a panel discussion on blockchain applications in cybersecurity.

Other speakers include the Ecosystem Manager of Arm, Chairman of the European Chamber of Commerce Taiwan, professors & academics from Taiwan top universities; as well as speakers from Qualcomm Incorporated, Nomura Research Institute and more. For more details on the InnoVEX Forum, please visit the InnoVEX website and save a seat for the InnoVEX Forum.

Exhibit, Pitch, Match, Expand

As an exhibition, InnoVEX always attracts hundreds of global startups and thousands of visitors. There are currently 467 InnoVEX exhibitors from 24 countries & regions. The top 5 industries of the teams are: AI, IoT, Health & Biotech, AR/VR/XR, and Consumer Tech.

Startups that will join InnoVEX include:

  • Beseye — an AI startup from Taiwan with focus on AI applications in security by identifying human faces, characteristics, behavior, and facial recognition.
  • WeavAir — an award-winning Canadian IoT startup that uses various metrics as well as predictive algorithms for indoor air quality management.
  • Klenic Myanmar — the first solution providing startup from Myanmar that improves healthcare efficiency and accuracy.
  • Veyond Reality — a startup from Taiwan that develops innovative educational solutions by utilizing AR/VR/XR.
  • Neonode Technologies — a Swedish startup that develops, manufactures, and sells sensor modules based on its patented optical reflective technology.

Visitors can get more information on all exhibiting startups in the InnoVEX website’s Exhibitors Directory page.

143 global startups from 19 countries and regions registered for the InnoVEX Pitch Contest where a prize pool of USD 420,000 awaits them. This year’s grand prize is the Taiwan Tech Award which is worth USD 100,000; sponsored by Taiwan Tech Arena (Ministry of Science and Technology). Other special prizes include the Startup Terrace Awards worth USD 60,000 for 5 startups; Taiwania Innovation Award for startups in IoT or biomedical field worth USD 10,000; and Qualcomm Innovation Award will be awarded to startups in AI & Big Data, AR/VR/XR, Hardware & IoT, or 5G applications, worth USD 10,000. The InnoVEX Pitch Contest Semifinal will be held in the Pi Stage on May 29 and May 30; while the Final stage will be held in the Center Stage on May 31.

Advertisement
Stake.com

The InnoVEX Pi Stage is the place for startup demonstrations, pitch, and matchmaking sessions. During the three days of InnoVEX, in total five events will be held in the Pi Stage to promote startups to the global stage and help them find opportunities around the world.

The Pi Stage will have 4 events in addition to the InnoVEX Pitch Contest Semifinal Stage:

  • May 30, 09:45 – 12:00: InnoVEX Matchmaking Powered by TTA x AAN: a matchmaking event for startups to meet international accelerators from Asia Pacific. The participating accelerators include: Startup GoGo, HKSTP, TinkBig Ventures, QBO Innovation Hub, and Schoolab.
  • May 30, 14:00 – 17:30: InnoVEX Matchmaking Powered by TTA x TIEC: an industrial matchmaking to connect startups with potential investors, partners, and more. The participating investors include: Taya Venture Capital, Darwin Ventures, CIDC Consultants Inc., SinoPac, and Samsung Next.
  • May 31, 10:00 – 12:00: Global Demo Day: a startup demo platform featuring startups from FrancePolandCanada, and Philippines. In addition, the participating trade offices will also introduce their startup programs in this event.
  • May 31, 13:00 – 17:00: Tourism Innovation & Awards: the final stage of a pitch contest supported by the Tourism Bureau under the Ministry of Transportation & Communications. This event aims to find the best method to enhance tourism through ICT applications.

Each event will aim to connect startups with potential investors, partners, and other resources to help them grow and expand globally; including exposure to and from global media. The events at Pi Stage are open for public participation and InnoVEX visitors are welcome to join the events to see the innovations from around the world.

Innovation Does not Stop at Sunset

InnoVEX is not limited to the showgrounds only. As deals, negotiations, and businesses do not stop at sunset; neither does InnoVEX. On May 30, InnoVEX will have a night networking party titled “InnoVEX Taiwan Tech @Night”. An exclusive invite-only event, the party will have invite VIPs from the InnoVEX organizer, government & trade office representatives, startups, global investors, leading ICT companies, and more to both network and relax. Invited guests will have the opportunity to enjoy the night citylights, good food, and music; all while networking, dealmaking, and matchmaking.

Join InnoVEX 2019 from May 29 to 31

Advertisement
Stake.com

InnoVEX 2019 is open for participation from everyone. Tech enthusiasts, young entrepreneurs, and the general public can enter the InnoVEX showgrounds with the COMPUTEX badge or InnoVEX pass. Get the entry pass in the InnoVEX website: http://innovex.computex.biz

 

SOURCE Taipei Computer Association (TCA)

Fintech PR

Invitation to presentation of EQT AB’s Q1 Announcement 2024

Published

on

invitation-to-presentation-of-eqt-ab’s-q1-announcement-2024

STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.

The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.

To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.

The webcast can be followed live here and a recording will be available afterwards.

Information on EQT AB’s financial reporting

Advertisement
Stake.com

The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.

The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.

Contact
Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]

Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334

This information was brought to you by Cision http://news.cision.com

Advertisement
Stake.com

https://news.cision.com/eqt/r/invitation-to-presentation-of-eqt-ab-s-q1-announcement-2024,c3956826

The following files are available for download:

https://mb.cision.com/Main/87/3956826/2712771.pdf

Invitation to presentation of EQT AB’s Q1 Announcement 2024

https://news.cision.com/eqt/i/eqt-ab-group,c3285895

Advertisement
Stake.com

EQT AB Group

 

View original content:https://www.prnewswire.co.uk/news-releases/invitation-to-presentation-of-eqt-abs-q1-announcement-2024-302109147.html

Continue Reading

Fintech PR

Kia presents roadmap to lead global electrification era through EVs, HEVs and PBVs

Published

on

kia-presents-roadmap-to-lead-global-electrification-era-through-evs,-hevs-and-pbvs
  • Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
  • Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
  • Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
    • Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
    • PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
  • Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
  • 2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
  • CEO reaffirms Kia’s commitment to ESG management

SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.

Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.

During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.

The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.

“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”

Advertisement
Stake.com

Photo – https://mma.prnewswire.com/media/2380039/Photo_1__2024_CEO_Investor_Day.jpg
PDF – https://mma.prnewswire.com/media/2380040/Press_Release__2024_Kia_CEO_Investor_Day_240405.pdf

Cision View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/kia-presents-roadmap-to-lead-global-electrification-era-through-evs-hevs-and-pbvs-302109142.html

Continue Reading

Fintech PR

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update

Published

on

biovaxys-technology-corp.-provides-bi-weekly-mcto-status-update

VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.

As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.

The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.

Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.

About BioVaxys Technology Corp.

Advertisement
Stake.com

BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.

ON BEHALF OF THE BOARD

Signed “James Passin
James Passin, Chief Executive Officer
Phone: +1 646 452 7054

Logo – https://mma.prnewswire.com/media/1430981/BIOVAXYS_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/biovaxys-technology-corp-provides-bi-weekly-mcto-status-update-302108920.html

Advertisement
Stake.com
Continue Reading

Trending